❮ Return to Our Work

Blog Post | January 11, 2022

The Case For Vaccine Equity

Executive BranchIntellectual PropertyPatent and Trademark OfficePharmaRevolving Door
The Case For Vaccine Equity

The Covid-19 pandemic has led to millions of deaths in the past two years. The hope that vaccines developed in record time — mostly through research funded by the U.S. federal government — would allow us to close this dark chapter continues to wane in the face of rich countries’ vaccine hoarding and pharmaceutical companies’ appetite for profit. This need not and must not be the case. The Biden administration has a historic opportunity to deal a serious blow to the pharmaceutical industry’s profiteering goals and act in the world’s interest. It would be unconscionable for them to do otherwise. 

To truly bring an end to the Covid-19 pandemic which has ravaged the globe, the Biden administration must embrace a strategy of vaccine equity. To do this, the Biden Administration needs to ensure the suspension of intellectual property restrictions on the coronavirus vaccines, via a serious push at the World Trade Organization. In addition to that, the administration must use its broad powers to fully challenge Pfizer and Moderna’s mRNA vaccine duopoly. That means compelling the beneficiaries of public largesse to share vaccine recipes and manufacturing know-how. It is perfectly legal for the federal government to do this without the firms’ buy-in. After all, significant portions of the research that led to development of these vaccines were funded by federal government grants and programs. The public funded research from which these firms have profited can now save many more lives if the lifesaving technology is better utilized. It is past time for Biden to act.

Below is the Revolving Door Project’s case for vaccine equity specifically and intellectual property reform more broadly. How the Biden Administration deals with these issues will go a long way to determining how they are remembered across the globe: Heroic reformers, or retrograde hacks content to stand with profiteers rather than the vulnerable.

This post will be updated over time.

Press Release

Biden Administration’s Inaction on Vaccine Equity is Cowardly and Shameful

Biden’s TRIPS Waiver Decision Is A Transformative, Hopeful Event

Break Big Pharma’s Stranglehold On COVID-19 Vaccines With Existing Powers, 16 Groups Tell Biden Admin

Big Pharma’s Coils Around COVID-19 Vaccines Likely Protected By Raimondo, Zients, Ricchetti

With Rumored USPTO Pick, Biden Prioritized Patronage Over Patent Reform

Zients Must Open-Source Vaccines To Prove Independence And Seriousness


16 Groups Tell Biden To Break Big Pharma’s Stranglehold On COVID-19 Vaccines With Existing Powers


How to Vaccinate the World

Place Human Lives Over Pharma’s Property Rights

Blog Posts

Why Is Politico’s Ryan Heath Carrying Water For Big Pharma Monopolies?

The Brother Of A Pharma Lobbyist Advises Biden As He Weighs Vaccine IP Waiver

Why You Should Care Who Leads the Patent and Trademark Office

Biden Can’t Pick A PTO Director Because Democrats Can’t Decide If They Like Big Pharma

Secretary Raimondo Must Act Quickly to Support the TRIPS Waiver

Do Not Give Gina Raimondo A Promotion

Revolver Spotlight: Kevin Rhodes

Revolver Spotlight: Ellisen Turner

Revolver Spotlight: Elizabeth Fowler

Revolver Spotlight: Jannie Lau

Revolver Spotlight: Chris Coons

Industry Agenda Reports

The Industry Agenda: Big Pharma

Image: “First vaccine against dengue vials production” by Sanofi Pasteur is licensed under CC BY-NC-ND 2.0

Executive BranchIntellectual PropertyPatent and Trademark OfficePharmaRevolving Door

More articles by Timi Iwayemi

❮ Return to Our Work